Biomimetic Nanoemulsion for Synergistic Photodynamic-Immunotherapy Against Hypoxic Breast Tumor.

Abstract

Photodynamic therapy (PDT) is commonly used as an "in situ vaccine" to enhance the response rate of PD-1/PD-L1 antibodies. Unfortunately, the high cost and adverse effects of these antibodies, and the hypoxic state of solid tumors limits the efficacy of synergistic photodynamic-immunotherapy. Here, we developed a biomimetic nanoemulsion camouflaged with a PD-1-expressing cell membrane for synergistic photodynamic-immunotherapy against hypoxic breast tumors. The perfluorocarbon of the nanoemulsion could provide oxygen as the source of PDT against hypoxic tumors. Moreover, co-delivering a photosensitizer and the PD-1 protein (substituting for a PD-L1 antibody) achieves the synergy effect of PDT and immunotherapy. Synergistic photodynamic-immunotherapy completely inhibited primary and distant subcutaneous 4T1 tumors, mechanistically by boosting the maturation of dendritic cells and tumor infiltration of cytotoxic T lymphocytes.

• Authors: Yifan Zhang, Yunyan Liao, Qinan Tang, Jing Lin, Peng Huang
• Journal: Angewandte Chemie (International ed. in English) (Angew Chem Int Ed Engl) Vol. 60 Issue 19 Pg. 10647-10653 (05 03 2021) ISSN: 1521-3773 [Electronic] Germany
• PMID: 33555085 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2021 Wiley-VCH GmbH.

Chemical References

• Antineoplastic Agents
• Emulsions
• Photosensitizing Agents

Topics

• Antineoplastic Agents (chemistry, therapeutic use)
• Biomimetic Materials (chemistry, therapeutic use)
• Breast Neoplasms (therapy)
• Emulsions (chemistry)
• Female
• Humans
• Immunotherapy
• Nanoparticles (chemistry)
• Photochemotherapy
• Photosensitizing Agents (chemistry, therapeutic use)